Retreatment with venetoclax and hypomethylating agents among AML patients who have relapsed after initial response and subsequent interruption of therapy

Leuk Lymphoma. 2020 Dec;61(14):3532-3533. doi: 10.1080/10428194.2020.1808213. Epub 2020 Aug 19.

Authors

Tamer A Othman¹, Jianying Zhang², Matthew Mei¹, Anthony S Stein¹, Stephen J Forman¹, Guido Marcucci¹, Vinod Pullarkat¹, Ibrahim Aldoss¹

Affiliations

¹ Gehr Family Center for Leukemia Research, Department of Hematology and Hematopoietic Cell Transplantation, City of Hope Medical Center, Duarte, CA, USA.
² Department of Information Sciences, City of Hope Medical Center, Duarte, CA, USA.

PMID: 32811233
DOI: 10.1080/10428194.2020.1808213

No abstract available

Publication types

Letter

MeSH terms

Bridged Bicyclo Compounds, Heterocyclic*
Humans
Leukemia, Myeloid, Acute* / drug therapy
Retreatment
Sulfonamides

Substances

Bridged Bicyclo Compounds, Heterocyclic
Sulfonamides
venetoclax